Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to

Recruiting

Phase 3

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Sponsor:

AstraZeneca

Code:

NCT06307665

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

BDA MDI

AS MDI

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-03. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-03-25.